What is HALO's five-year median P/S?

7.6x. Half of HALO's weekly readings over the last five years were higher and half were lower. This page has 742 weekly readings, from Aug 6, 2012 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares HALO only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Halozyme Therapeutics Inc (HALO) P/S ratio history

Health Care

$125.63

Latest weekly close · Market cap $15.2B

Above its usual range

As of Oct 24, 2026

HALO's P/S of 9.2x is higher than 71% of its weekly readings over the last five years.

Weekly P/S with its 5-year range

P/S each weekMiddle half of the last 5 years5-year median 7.6×

5-year median: 7.6×
10-year median: 9.2×
5-year low to high: 5.4×–15.5×
Versus 5-year median: +21%

P/S

71stpercentile

of its weekly readings over the last five years

Above its usual range

Growth, last 12 months vs the year before

Revenue: +41%accelerating
EPS: -22%

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

P/S at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

HALO P/S at each year-end
Year-end	P/S	5-year percentile
Dec 29, 2025	6.9×	30
Dec 30, 2024	6.6×	11
Dec 25, 2023	6.4×	2
Dec 26, 2022	13.7×	42
Dec 27, 2021	12.7×	24
Dec 28, 2020	30.4×	98
Dec 30, 2019	n/a	Too little history
Dec 31, 2018	7.5×	6
Dec 25, 2017	16.2×	65
Dec 26, 2016	n/a	Too little history

Health Care peers on P/S

Each percentile compares a stock with its own last five years.

Compare HALO with peers

Health Care peers of HALO on P/S
Stock	P/S	Versus its own history	5-year percentile
ABBVAbbVie	7.8×	Historically high	100
AMGNAmgen	6.4×	Historically high	99
ARWRArrowhead Pharmaceuticals Inc	12.4×	Within its usual range	33
BBIOBridgebio Pharma Inc	18.8×	Below its usual range	17
BIIBBiogen	3.7×	Above its usual range	80

Appears in

Sector: Health Care
Screens: Stocks with Low P/E Ratios and Steady Revenue Growth
Stocks Below Their 5-Year Median P/E
Stocks Near Their Lowest P/E Ratios in 5 Years

Screen Health Care stocks the same way

Research on HALO

No articles about HALO yet. How valuation percentiles work

Loading peers and related research…

About this history

What is HALO's current P/S?: HALO's P/S of 9.2x is higher than 71% of its weekly readings over the last five years.
What is HALO's five-year median P/S?: 7.6x. Half of HALO's weekly readings over the last five years were higher and half were lower. This page has 742 weekly readings, from Aug 6, 2012 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares HALO only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.